Lung cancer, platinum analog-based frontline treatment and pharmacogenetic limitations

Personalized Medicine · Published 2024-11-01 · DOI 10.1080/17410541.2024.2391269

Authors being retrieved — see the publisher record. https://doi.org/10.1080/17410541.2024.2391269

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2024

Related articles

• Targeting a novel metabolic vulnerability of non-small cell lung cancer to fatty acid oxidation surmounts chemoresistance · Drug Resistance Updates · 2026 · Cites or is cited by this article
• From genomes to metabolomes: adaptive science in personalized medicine · Personalized Medicine · 2026 · Same journal
• Polygenic risk scores to refine Breast cancer screening and prevention strategies · Personalized Medicine · 2025 · Same journal
• Genomics and the early diagnosis of lung cancer · Personalized Medicine · 2025 · Same journal
• Leveraging circulating microRNAs for personalized disease-modifying therapies in type 1 diabetes · Personalized Medicine · 2025 · Same journal
• Homozygous GBA1 p.T82I variant in type 1 Gaucher disease: clinical and biochemical characterization · Personalized Medicine · 2025 · Same journal
• Awareness, and interest in personalized medicine: a cross-sectional survey study of health professionals · Personalized Medicine · 2025 · Same journal
• Optimizing breast cancer therapy: chemoressitance and machine learning for precision prediction · Personalized Medicine · 2025 · Same journal
• Global harmonization in advanced therapeutics: balancing innovation, safety, and access · Personalized Medicine · 2025 · Same journal
• Epigenetic and genetic insights for tailored therapeutic strategies in multiple sclerosis · Personalized Medicine · 2026 · Same journal